MN4000 for Treatment of CF and MND Patients in the Home Setting: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for MN4000 for Treatment of CF and MND Patients in the Home Setting (NCT03797677), a na na study. The primary outcome is Patient / Caregiver Satisfaction Scores.

2. Clinical Question

This was a pilot study, not a randomized comparison. It also collected clinical outcome data before, during, and after treatment, including measures of lung function, disease-related quality of life, functional status, adherence, and pulmonary exacerbations. The registry record does not provide results for those outcomes. Consequently, the primary question that can be identified from the record is about how satisfaction was assessed, rather than what satisfaction scores were observed or how they changed.

3. Trial Design

The registry describes a completed, non-randomized, open-label pilot study conducted at one US site. Its design is identified as observational and single group: all enrolled participants received MN4000 treatment at home. The record lists cystic fibrosis and motor neuron disease groups, each described as receiving home-based airway clearance with Metaneb. Because neither group is an untreated or alternative-treatment control, differences between the disease groups would not isolate an effect of the device.

The registry reports enrollment of 10 participants. It lists the study start as 2017-03-09 and primary completion as 2017-11-30. The treatment period relevant to the primary endpoint was 90 days. The record does not report a trial phase beyond NA, and allocation is also listed as NA. Masking is listed as none, consistent with the open-label description.

The primary efficacy variable was patient and/or caregiver satisfaction with therapy, assessed using a Therapy Use Rating Questionnaire. The record says the questionnaire assessed change in satisfaction or effectiveness across a variety of parameters. Patients completed it when possible; caregivers could respond on behalf of patients unable to answer. The study also collected clinical outcome data at times before, during, and after the treatment period.

The registry lists secondary outcomes that include adherence, ALS-Functional Rating Scale, Cystic Fibrosis Questionnaire - Revised, pulmonary exacerbations, and actual and predicted FEV1 and FVC. It records 16 outcome measures, but does not provide results for these measures. The record lists no statistical analyses. Details about recruitment procedures, eligibility criteria beyond the stated need for regular home airway-clearance therapy, and the statistical analysis plan are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Patient / Caregiver Satisfaction Scores, measured over 90 days.

The primary endpoint is titled Patient / Caregiver Satisfaction Scores, with the unit described as participants and a 90-day timeframe. The registry identifies the Therapy Use Rating Questionnaire as the instrument. Its stated purpose was to assess change in satisfaction or effectiveness across a variety of parameters. This makes the endpoint a report of how patients or caregivers experienced therapy, rather than a direct measure of lung function or a clinical event.

The person completing the questionnaire depended on whether the patient could respond. The patient was asked to complete it if possible. Because motor neuron disease can compromise a patient’s ability to interact and answer questions, a caregiver could respond on the patient’s behalf when needed. The record does not report how many responses came from patients versus caregivers, how this distinction was handled in analysis, or whether a particular scoring rule combined the responses.

Patient- or caregiver-reported satisfaction can capture aspects of therapy use that clinical measurements alone may not describe. However, interpretation depends on the questionnaire’s scoring, the timing and completeness of responses, and how changes are summarized. Those details, as well as the actual scores and their distribution, are not reported in the registry record. The endpoint’s name and description therefore establish what the study intended to assess, but do not establish the level of satisfaction observed.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry identifies an observational, non-randomized, open-label, single-group pilot study. It lists no statistical analyses. Statistical concepts can still help explain what information would be needed to interpret its outcomes, but those concepts should not be mistaken for methods documented as having been used in this study.

What does an open-label, single-group design imply?

In an open-label study, participants and the people assessing or delivering treatment are not masked to the treatment being used. In a single-group design, there is no separate control group assigned to a different treatment or to no treatment. Here, the record says all enrolled participants received the MN4000. The disease-specific groups do not create a treatment comparison: both are described as receiving the device.

General statistical explanation: a comparison group can help distinguish changes associated with treatment from changes that may have occurred over time for other reasons. Random allocation, when used, can also help make groups comparable with respect to both measured and unmeasured factors. Neither a randomized allocation nor an untreated or alternative-treatment comparator is described in this record. This means the design is suited to describing the pilot experience, but it cannot by itself establish that an observed change was caused by the device.

What would a satisfaction score summarize?

The primary endpoint uses a Therapy Use Rating Questionnaire to assess satisfaction or perceived effectiveness across a variety of parameters. A score is a summary of responses under a defined scoring rule. To interpret a score, readers generally need to know how questionnaire items are combined, what score values mean, whether higher or lower values indicate a more favorable response, and how missing answers are handled. These scoring details and the observed scores are not reported in the registry record.

General statistical explanation: a group average can describe a typical response but may conceal substantial variation among participants. A distribution, range, or other summary can show whether responses were clustered or varied. A confidence interval, when reported, describes the precision of an estimated quantity under the statistical model used; it does not guarantee that the estimate is free of bias. No satisfaction estimate or confidence interval is reported in the registry record.

Why does the response source matter?

The record permits a caregiver to respond when a patient cannot answer. This can make outcome collection possible for patients with communication or interaction limitations, but patient and caregiver reports may not be interchangeable. General statistical practice would make clear who provided each response and how proxy responses were handled. The registry record does not report the number of patient responses and caregiver responses, or whether they were analyzed separately.

How should the planned clinical measures be understood?

The secondary outcomes include adherence, ALS-Functional Rating Scale, Cystic Fibrosis Questionnaire - Revised, pulmonary exacerbations, and actual and predicted FEV1 and FVC. These measures describe different domains and do not share a common scale. Lung-function measurements, questionnaires, functional ratings, adherence, and event counts require outcome-specific summaries and interpretation. The registry record lists 16 outcome measures but does not report their results or the statistical analyses used for them.

General statistical explanation: for continuous measurements, an estimate of a mean change may be accompanied by a measure of uncertainty and by information about the observations contributing to it. For counts or binary outcomes, the number of events and the number of participants assessed provide essential context. Repeated measurements also require attention to their timing and to the correlation between observations from the same participant. The record does not report the analysis methods or sufficient results to determine how these considerations were addressed.

What do the planning assumptions mean?

The registry’s planning description refers to an illustration based on an observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. It describes considering a stated fraction of the observed effect. The record does not report numerical planning results or the observed effect used for that illustration. These planning assumptions are not evidence that the trial itself used a two-arm design: the study is described as single group, and all enrolled participants received the device.

General statistical explanation: sample-size calculations describe a hypothetical study design under chosen assumptions about the effect to detect, variability, significance level, allocation, and desired power. They are planning illustrations, not observed power and not a substitute for the trial’s actual outcome estimates. They cannot supply missing results or establish that a pilot was adequately powered. The registry record does not report a statistical plan or sample-size justification for the pilot itself.

Because the registry lists no analyses and does not report endpoint results, statistical interpretation must remain descriptive. No recalculated effect estimate or uncertainty measure is available to compare with a sponsor analysis. The record does not describe an adjustment for covariates, repeated measurements, or multiple outcomes.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 16 outcome measures. The primary outcome is patient or caregiver satisfaction, and the listed secondary outcomes include adherence, ALS-Functional Rating Scale, Cystic Fibrosis Questionnaire - Revised, pulmonary exacerbations, and actual and predicted FEV1 and FVC. Considering multiple outcomes can raise the chance of finding an apparently notable result by chance if many statistical tests are performed. General statistical practice may address this through a prespecified hierarchy, adjustment, or cautious interpretation of exploratory analyses. The registry record does not report a multiplicity strategy, and it lists no statistical analyses.

Missing-data handling is also not reported in the registry record. For the satisfaction measure, the record allows caregiver responses when patients cannot respond, but does not state how unanswered questionnaire items, missed visits, or unavailable follow-up measurements were handled. It does not report completion rates for the questionnaire or the other outcome measures. A reported count or average can be difficult to interpret without knowing how many participants contributed data and whether missingness may be related to health status or ability to respond.

The record does not identify analysis populations, such as a population defined by enrollment, treatment received, or outcome availability. Although all enrolled participants are described as receiving treatment, the record does not say which participants were included in each outcome analysis. The registry reports enrollment of 10 participants but does not report outcome-specific denominators. Consequently, neither the completeness of follow-up nor the representativeness of any analyzed group can be assessed from the record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry lists serious and other adverse event counts separately for the cystic fibrosis and motor neuron disease groups. For each group, the number at risk is 5, the number affected by a serious adverse event is 0, the number affected by another adverse event is 0, and deaths are listed as 0. These are the event figures recorded for the groups; they should not be read as a comparison between treatments, because both groups received home-based airway clearance with Metaneb.

A zero recorded count means that the registry reports no participants with the relevant event in that group. It does not, by itself, establish that no event occurred outside the recorded ascertainment, nor does it indicate how completely participants were followed or how events were sought and classified. The registry record does not provide event narratives, timing, severity detail beyond the serious-event category, or information about the method of safety surveillance.

With a pilot of this size and no control group, the safety counts are descriptive. They cannot establish comparative risk or exclude uncommon events. The record does not report additional statistical analyses of adverse events.

12. What the Result Does, and Does Not, Mean

This study is informative as a description of a home-use pilot involving participants with cystic fibrosis or motor neuron disease who required regular airway-clearance therapy. It documents an open-label, non-randomized approach, identifies patient or caregiver satisfaction as the primary endpoint, and lists clinical and adherence outcomes. The registry also records adverse event counts by disease group.

However, the primary satisfaction results are not reported in the registry record. There is no reported score, change estimate, distribution, or statistical uncertainty to interpret. Results for the listed secondary outcomes are also not reported. As a result, readers cannot determine from this record what satisfaction participants or caregivers expressed, how adherence was observed, or what changes occurred in lung function, functional status, questionnaire scores, or pulmonary exacerbations.

The study design also sets limits on what any change could mean. All participants received the device, and the two groups represent different conditions rather than treatment and control. Without a randomized comparator, a change over time cannot be separated from other influences on the outcome. The open-label approach is particularly relevant to a subjective satisfaction measure, because respondents know that the treatment is being used. The registry record does not report procedures intended to address these interpretive challenges.

The recorded safety counts are limited to the categories and group counts listed. They are not comparative safety estimates and cannot establish that adverse events are absent more broadly. Nor does a completed status establish that every planned outcome was measured or that the relevant results were posted.

Accordingly, the record describes what the pilot set out to assess and reports a limited set of event counts, but it does not provide the outcome data needed to quantify satisfaction or clinical changes. It should not be treated as evidence of a treatment effect or as a controlled assessment of benefit or risk.

13. Why This Trial Matters Statistically

Pilot studies can be statistically useful for describing whether a study approach has been attempted in a particular setting and for identifying outcomes that may be important to participants and caregivers. This registry record documents home-based treatment, an open-label observational design, a satisfaction-focused primary endpoint, and collection of clinical outcomes before, during, and after the treatment period. It also makes clear that the two disease groups are not treatment comparators.

The record is also a reminder that endpoint descriptions and endpoint results are different kinds of information. A questionnaire may be named, its timeframe stated, and its intended purpose explained, while the scores needed to understand the observed experience remain unavailable. Similarly, listing lung-function and questionnaire outcomes does not establish what those outcomes showed. Statistical conclusions depend on estimates, denominators, variability, and analysis methods, none of which are reported for the primary endpoint.

The design matters because statistical comparisons rely on what groups were formed and how. In this study, all participants received the device. The disease-specific groups cannot be interpreted as a controlled contrast, and an observed before-and-after pattern, if available, would not by itself distinguish treatment-related change from other influences. The small pilot scale and single-site setting also mean that any reported experience would need cautious interpretation beyond the participants studied.

Finally, the registry’s limited safety counts illustrate why zero recorded events should be read descriptively rather than as proof of no risk. Together, these features make the record valuable for understanding the study’s question and design, while also defining why it cannot provide a quantitative treatment-effect conclusion.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most important limitation for interpreting this trial is that the registry record does not report the primary satisfaction scores or results for the secondary outcomes. No effect estimates, uncertainty intervals, outcome-specific denominators, or statistical analyses are listed. As a result, the intended outcomes cannot be quantitatively assessed from this record.

The study was non-randomized, open label, observational, and single group. All enrolled participants received the MN4000, and the cystic fibrosis and motor neuron disease groups do not serve as control and treatment groups. Without a randomized comparator, changes over time would be vulnerable to alternative explanations. The open-label design is also relevant to a patient- or caregiver-reported satisfaction endpoint.

The registry describes a pilot conducted at one US site, with enrollment of 10 participants. The record does not report details of participant selection, the number approached or screened, reasons for non-participation, or follow-up completion. It also does not state how many satisfaction responses came from patients versus caregivers, how questionnaire scores were calculated, or how missing responses were handled.

Although the registry lists 16 outcome measures, it does not report a statistical analysis plan, a multiplicity strategy, or analysis populations. The sample-size planning description is an illustration and does not report numerical planning results; it is not the design of the single-group pilot. Safety information is limited to the listed event counts and does not include event descriptions or further ascertainment details. These gaps restrict assessment of precision, completeness, and the scope of conclusions that can be drawn.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: MN4000 for Treatment of CF and MND Patients in the Home Setting — NCT03797677.
• Registry record last updated 2024-08-07; status last verified 2024-07.
• Results first posted 2024-08-07.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a completed, open-label, non-randomized pilot of home-based MN4000 treatment for patients with cystic fibrosis or motor neuron disease who required regular airway-clearance therapy. It lists enrollment of 10 participants at one US site. All enrolled participants received treatment; the disease-specific groups are not a control comparison. The primary endpoint was patient or caregiver satisfaction on a Therapy Use Rating Questionnaire over 90 days. Clinical and adherence outcomes were also collected.

The record lists 16 outcome measures and no statistical analyses. It does not report satisfaction scores or results for the listed secondary outcomes. For each disease group, the registry lists 5 participants at risk, 0 affected by serious adverse events, 0 affected by other adverse events, and deaths of 0. These safety figures are descriptive and do not establish comparative risk. The record supports describing the study design and intended assessments, but not estimating treatment effects.